NeoImmuneTech, Inc. (KOSDAQ:950220)
South Korea
· Delayed Price · Currency is KRW 1,067.00
+1.00 (0.09%)
May 14, 2025, 10:40 AM KST
NeoImmuneTech Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Revenue | 170.38 | - | - | - | - | Upgrade
|
| Gross Profit | 170.38 | - | - | - | - | Upgrade
|
| Selling, General & Admin | 36,534 | 52,369 | 55,326 | 50,090 | 8,134 | Upgrade
|
| Research & Development | - | - | - | - | 22,704 | Upgrade
|
| Operating Expenses | 41,143 | 55,847 | 58,182 | 51,906 | 31,270 | Upgrade
|
| Operating Income | -40,972 | -55,847 | -58,182 | -51,906 | -31,270 | Upgrade
|
| Interest Expense | -726.09 | -225.28 | -261.39 | -219.15 | -185.79 | Upgrade
|
| Interest & Investment Income | 1,788 | 2,877 | 1,154 | 390.88 | 952.88 | Upgrade
|
| Currency Exchange Gain (Loss) | -1,335 | -128.89 | -3,005 | -589.4 | -79.28 | Upgrade
|
| Other Non Operating Income (Expenses) | 1,187 | 23.06 | 18.52 | 15.46 | 0.35 | Upgrade
|
| EBT Excluding Unusual Items | -40,059 | -53,301 | -60,276 | -52,308 | -30,582 | Upgrade
|
| Gain (Loss) on Sale of Assets | -321.85 | -1.91 | -13.03 | -104.72 | 152.62 | Upgrade
|
| Asset Writedown | -488.92 | - | - | - | - | Upgrade
|
| Pretax Income | -40,870 | -53,303 | -60,289 | -52,413 | -30,429 | Upgrade
|
| Income Tax Expense | 12.83 | 101.3 | 116.41 | 69.47 | 27.29 | Upgrade
|
| Net Income | -40,883 | -53,405 | -60,406 | -52,482 | -30,456 | Upgrade
|
| Net Income to Common | -40,883 | -53,405 | -60,406 | -52,482 | -30,456 | Upgrade
|
| Shares Outstanding (Basic) | 99 | 99 | 99 | 95 | 83 | Upgrade
|
| Shares Outstanding (Diluted) | 99 | 99 | 99 | 95 | 83 | Upgrade
|
| Shares Change (YoY) | -0.22% | 0.06% | 3.68% | 15.27% | 1.50% | Upgrade
|
| EPS (Basic) | -414.60 | -540.40 | -611.60 | -550.94 | -368.52 | Upgrade
|
| EPS (Diluted) | -414.60 | -540.40 | -611.60 | -550.94 | -368.52 | Upgrade
|
| Free Cash Flow | -43,768 | -50,552 | -44,881 | -36,596 | -29,993 | Upgrade
|
| Free Cash Flow Per Share | -443.86 | -511.54 | -454.42 | -384.18 | -362.92 | Upgrade
|
| Gross Margin | 100.00% | - | - | - | - | Upgrade
|
| Operating Margin | -24047.07% | - | - | - | - | Upgrade
|
| Profit Margin | -23994.58% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | -25688.01% | - | - | - | - | Upgrade
|
| EBITDA | -37,014 | -52,637 | -55,380 | -50,033 | -30,282 | Upgrade
|
| D&A For EBITDA | 3,959 | 3,210 | 2,802 | 1,873 | 987.98 | Upgrade
|
| EBIT | -40,972 | -55,847 | -58,182 | -51,906 | -31,270 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.